Posted on

The Trip of a Lifetime

DOSED 2 Screening with Dr. Gabor Maté & Dennis McKenna Q&A

Mark your calendar – DOSED 2: The Trip of a Lifetime is coming to the Vogue Theatre in Vancouver on  August 3rd! 

If you haven’t seen the original DOSED, check it out here. The award-winning documentary follows a woman overcoming opioid addiction with psilocybin and iboga.

DOSED 2 shares the remarkable story of a terminally-ill cancer patient who was granted the right to try psilocybin mushrooms to treat her end of life anxiety.

The special event premiere screening will be followed by an audience Q&A with:

  • Renowned addiction expert and author Dr. Gabor Maté
  • Legendary psychonaut Dennis McKenna
  • Psychedelic therapist (and your fave Daily Mushroom Podcast guest) Dave Phillips
  • Patient Laurie Brooks
  • Filmmakers Tyler Chandler & Nicholas Meyers
  • And more!

Get screening tickets

Watch the DOSED 2 trailer

Posted on

Enveric Biosciences Expands Portfolio of Drug Development Candidates and Files New Provisional Patent Application

Enveric Biosciences Expands Portfolio of Drug Development Candidates and Files New Provisional Patent Application

NAPLES, Fla., March 29, 2022 /CNW/ –Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience company developing next-generation, psychedelic-inspired mental health medicines, announces the filing of a provisional patent application based on new discoveries by the Company.

The application describes more than 100 novel individual molecules and, if the broadest claims are allowed, could protect more than 10,000 possible new drug development candidates. The patent application and claimed drug candidates fall into the Company’s EVM201 second-generation, psychedelic-derived drug development program, with an initial target indication of cancer-related distress (CRD) and the potential to be expanded into additional mental health indications.

Dr. Peter Facchini, Ph.D., Chief Innovation Officer at Enveric, noted, “Our proprietary PsyAI™ artificial intelligence technology was used to design and provisionally rank a large and diverse collection of psychedelic-inspired molecules for further development. The majority of these new molecules, all of which are protected by this most recent provisional patent application, have already been synthesized in quantities sufficient to evaluate their safety and pharmacological properties, including receptor-binding profiles and behavioral analyses in animals. Based on our extensive in silico and experimental data, we are hopeful that we can nominate our lead candidates for entry into Enveric’s EVM201 preclinical development later this year.”

About Cancer Related Distress
The aim of palliative care for patients with cancer is to alleviate suffering.1 Patients facing life-threatening illness often feel hopeless, powerless, and demoralized.1 They suffer clinically significant anxiety and depression, and the resulting existential distress can lead to a loss of meaning or purpose in life and a desire for hastened death.1 As many as 1 in 2 patients with cancer experience significant psychological distress, collectively referred to as Cancer Related Distress (CRD).2 Available treatments for psychological distress have had limited efficacy in patients with cancer. 1 Psychedelic-assisted therapy has recently shown exceptional promise in helping to alleviate the psychological and existential burdens, including CRD, that many patients with life-threatening illnesses face every day.1

References:

  1. Rosenbaum D, Boyle AB, Rosenblum AM, Ziai S, Chasen MR. Psychedelics for psychological and existential distress in palliative and cancer care. Curr Oncol. 2019;26(4):225-226. Doi: 10.3747/co.26.5009
  2. Mehnert S, Hartung TJ, Friedrich M, et al. one in two cancer patients is significantly distressed: prevalence and indicators of distress. Psycho-Oncology. 2018;27(1):75-82. Doi: 10.1002/pon.4464

About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is a cutting-edge neuroscience company developing next-generation psychedelic-inspired mental health medicines. Enveric’s robust pipeline supports drug development from the clinic to commercialization for millions of patients in need around the world suffering from conditions that include cancer-related distress, PTSD, and more. For more information, please visit www.enveric.com.

Forward-Looking Statements
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans”, ” expects” or “does not expect”, “proposed”, “is expected”, “budgets”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability to achieve the value creation contemplated by technical developments; the impact of the novel coronavirus (COVID-19) on Enveric’s ongoing and planned clinical trials; the geographic, social and economic impact of COVID-19 on Enveric’s ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; Enveric’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to Enveric’s products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Cision View original content:https://www.prnewswire.com/news-releases/enveric-biosciences-expands-portfolio-of-drug-development-candidates-and-files-new-provisional-patent-application-301512358.html

SOURCE Enveric Biosciences

Posted on

Blackhawk Subsidiary Digital Mind Technology Starts Phase 1 Development of Digital Therapeutic Platform and is on Track for Completion in Q2, 2022

Blackhawk Subsidiary Digital Mind Technology Starts Phase 1 Development of Digital Therapeutic Platform and is on Track for Completion in Q2, 2022

  • Phase 1 development of new digital therapeutic platform underway 
  • Pilot study in 69 patients completed 
  • Helping cancer patients live better with pain 
  • Improved mental health outcomes in pain management 

Vancouver, British Columbia – TheNewswire – February 17, 2022 – Blackhawk Growth Corp. (CSE:BLR); (CNSX:BLR.CN); (OTC:BLRZF); (Frankfurt:0JJ) (the “Corporation” or “Blackhawk”), is pleased to announce that its subsidiary, Digital Mind Technology Pty. Ltd. (“DMT”) has started its phase 1 development of a digital therapeutic application designed for treating cancer patients experiencing pain and at risk of mental health disorders. DMT expects to complete phase 1 in Q2, 2022,

DMT’s clinical trials in cancer patients aim to develop a mindfulness intervention that is useful in pain management.  Pain, endured for any length of time unsustainably can result in low mood and lead to depression, anxiety and other related mental health disorders.  The mindfulness intervention will be designed to manage negative patterns of thoughts and behaviours.

With pain being one of the most common symptoms reported by nearly 70% of cancer patients1, DMT is creating a digital therapeutic application and web platform between patients and clinicians that can be used by patients to more effectively deal with pain.

Cancer pain remains a challenging symptom occurring long after treatment completion, with a prevalence of 20-50% in cancer survivors.2  The burden of mental health disorders appearing as a co-morbidity in cancer patients is high with around a quarter of cancer patients experiencing depression 3-5.  A cancer diagnosis is life changing and in itself is a source of considerable psychological and emotional distress.

Dr Russell says: “In our pilot clinical trial in 69 patients, we saw that a digital therapeutic was helpful in treating cancer patients cope with fear of cancer recurrence. We are progressing well with our digital therapeutics platform to help cancer patients cope with pain that will have substantial benefit to mental health and wellbeing”.

  1. Van Den Beuken-Van MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. Journal of pain and symptom management. 2016;51(6):1070-1090. e1079. 
  2. Gallaway MS, Townsend JS, Shelby D, Puckett MC. Peer Reviewed: Pain Among Cancer Survivors. Preventing Chronic Disease. 2020;17. 
  3. Naser AY, Hameed AN, Mustafa N, et al. Depression and Anxiety in Patients With Cancer: A Cross-Sectional Study. Frontiers in Psychology. 2021;12(1067). 
  4. Pitman A, Suleman S, Hyde N, Hodgkiss A. Depression and anxiety in patients with cancer. BMJ. 2018;361:k1415. 
  5. Hartung TJ, Brähler E, Faller H, et al. The risk of being depressed is significantly higher in cancer patients than in the general population: Prevalence and severity of depressive symptoms across major cancer types. European Journal of Cancer. 2017;72:46-53. 

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, TERP Wholesale LLC, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, Digital Mind Therapeutics and MindBio Therapeutics, as well as a share position in Gaia Grow Corp. (CSE:GAIA).

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A  

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the development of a digital therapeutic application by Digital Mind Technology Pty. Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Copyright (c) 2022 TheNewswire – All rights reserved.

Posted on

Enveric Biosciences and University of Calgary Collaborate on a Groundbreaking Clinical Trial for EVM-101 in Cancer Related Distress

Enveric Biosciences and University of Calgary Collaborate on a Groundbreaking Clinical Trial for EVM-101 in Cancer Related Distress

Enveric Biosciences (ENVB) will partner with the University of Calgary to study oral psilocybin for cancer-related distress. Patient enrollment will begin by the end of this year or early next year.

Enveric Biosciences

PDF of article

Posted on

Lawsuit against DEA for denying psilocybin access rejected

Federal Appeals Court Dismisses Cancer Patients’ Case To Use Psilocybin Under Right-To-Try Laws

A lawsuit filed by a physician and his cancer patients against the DEA for denying access to psilocybin therapy was rejected by the Court of Appeals.

The panel of judges determined that the agency is not at fault because it does not have the authority to waive the Controlled Substances Act.

PDF of article

Posted on

A better solution for cancer patients

B.C.’s functional and psychedelic mushroom industry is having a shroom boom

Antidepressants are often ineffective and can even interfere with cancer treatment drugs.

“Psychedelics are proving to not conflict with the cancer drug and are more effective than normal antidepressants generally,” according Frank Lane, director of Albert Labs. 

That’s why the BC-based company wants to bring a psilocybin treatment for cancer patients to European markets.

Albert Labs is expected to begin trading on the CSE early next year under the ticker ’ABRT’.

PDF of article

Posted on

Blackhawk Growth Fully Funds Phase II Clinical Trials in Psychedelics and Begins Development of Digital Mental Health Treatments

Blackhawk Growth Fully Funds Phase II Clinical Trials in Psychedelics and Begins Development of Digital Mental Health Treatments

Vancouver, British Columbia – TheNewswire – December 13, 2021 – Blackhawk Growth Corp. (CSE:BLR); (CNSX:BLR.CN); (OTC:BLRZF); (Frankfurt:0JJ) (“Blackhawk”), is pleased to provide an update on its clinical trials for both of its wholly-owned subsidiaries MindBio Therapeutics PTY Ltd. (“MindBio”) and Digital Mind Technology PTY Ltd. (“Digital Mind”).

MindBio Clinical Trial Update

MindBio is accelerating its clinical trial program and is now fully funded for its Phase II clinical trial for microdosing of psychedelics in late-stage cancer patients. MindBio will be one of only a handful companies that is progressing to a Phase II clinical trial in the psychedelics sector.

The now fully funded Phase II clinical trial will examine the effects of Psychedelic Microdosing Assisted Meaning Centred Psychotherapy (PMA-MCP) in advanced stage cancer patients.

The ground-breaking Phase II trial will examine the feasibility, acceptability and safety of a randomised, double-blind, placebo-controlled trial comparing Psychedelic Microdosing Assisted Meaning Centred Psychotherapy (PMA-MCP) to placebo in advanced stage cancer patients. This trial will help to evaluate whether PMA-MCP provides benefits in advanced stage cancer patients in regard to quality of life, their spiritual well-being, anxiety, depression, hopelessness, and attitudes towards death.

At each quarterly reporting, the intellectual property protection will be discussed and managed between the University of Auckland and MindBio. A qualified medical officer, psychotherapists, and a study nurse will also be appointed for patient therapy and safety.

In addition, MindBio also has the necessary funding to start the development of a second Phase II microdosing depression trial. This will involve the analysis of Phase I trial data, expected to be completed in Q1 2022, which will inform the trial design for Phase II trials for the development of investigator materials and the development of trial protocol documentation.

A pharmacogenomic (liver enzyme genotyping) and pharmacokinetic analyses will also be conducted to help understand the individual variability of response to LSD observed in Phase I study data (see Vizeli et al 2021 Scientific Reports). Furthermore, biomarker analysis will be used to determine potential candidate biomarkers for Phase 2 trials (e.g. mRNA).

MindBio has budgeted to start scientific research to objectively determine the effectiveness of psychedelic microdosing on individuals. This includes developing a platform to ensure time critical requirements of microdosing, personalised algorithms used for optimising microdosing to suit a given individual, artificial intelligent toos for data analytics for studying the impact of therapy on the patient’s mood state, and more.

Digital Mind Technology

Digital Mind has successfully completed a pilot randomized controlled trial with 69 patients of an online mindfulness-based program for people diagnosed with melanoma1. Led by leading scientist Dr. Lahiru Russell, Digital Mind is launching a fully funded Phase I clinical trial of mindfulness-based digital programs for people requiring pain management to avoid or reduce the impact on mental health. The clinical trials will start in Q1, 2022 and will be fully compliant with the Food and Drug Administration’s (FDA) protocols.

Results of Digital Mind’s completed pilot randomized controlled trial showed that psycho-educational interventions can decrease anxiety and health-related distress, and prompt positive change in coping with illness. Improving awareness of thoughts may be a therapeutic approach to reduce worrisome and unhelpful thoughts, which underlie fear of disease that can lead to depression and other mental health problems.

This awareness is an essential component of mindfulness-based interventions in which one is aware of any thoughts, feelings, bodily sensations and surrounding environment occurring moment-by-moment. In this state of awareness, thoughts and feelings are experienced as passing events in the mind, instead of a reflection of oneself or reality. This detached self-observation allows individuals to reflect on situations and respond in more adaptive ways, instead of reacting in an automatic, habitual pattern.

Online and digital based interventions are more easily accessible, available at any time to people in their own environment, enable people to work at their own pace and have the option to remain anonymous. Digital Mind’s Phase I clinical trial will build on the results of the pilot trial and protocols to help develop digital platforms (mobile, smart watch, and web) that provides clinically proven mindfulness-based digital programs to help patients deal with pain that ultimately reduces the impact on their mental health conditions. These clinical programs have the potential to be provided to patients via health professionals in a clinical setting.

“MindBio has taken a significant leap forward”, said Frederick Pels, CEO of Blackhawk Growth. “A fully funded Phase II clinical trial puts the research and progress of MindBio in the top echelon of the booming psychedelic sector. Combined with the addition of Digital Mind and its fully funded Phase I clinical trial, it truly displays the strength and growth of our Company’s psychedelic and life science portfolio. I look forward to updating shareholders as these initiatives progress and as we work hard to unlock substantial value for our shareholders.”  

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, MindBio Therapeutics and Digital Mind Technology.

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A  

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

  1. https://www.researchgate.net/publication/329333517_A_pilot_randomised_controlled_trial_of_an_online_mindfulness-based_program_for_people_diagnosed_with_melanoma 

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to future operations of Digital Mind Technology Pty Ltd. and MindBio Therapeutics Pyy Ltd The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Posted on

Blackhawk Growth’s MindBio Therapeutics Completes Safety Milestone In Its Phase 1 Clinical Trials

Blackhawk Growth’s MindBio Therapeutics Completes Safety Milestone In Its Phase 1 Clinical Trials

Vancouver, British Columbia – TheNewswire – November 08, 2021 – Blackhawk Growth Corp. (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt:0JJ) (the “Corporation” or “Blackhawk”), is pleased to announce that its wholly owned subsidiary, MindBio Therapeutics Pty Ltd (“MindBio”), has received feedback from the trial’s independent Data and Safety Monitoring Committee that the Phase 1 clinical trial is approved to continue after a successful six month safety review.

MindBio is a multi-disciplinary company pioneering new treatments for mental health conditions using psychedelic medicines, technology assisted mental health interventions and psychedelic assisted psychotherapies.

MindBio is currently undertaking the world’s first clinical trial of its kind microdosing LSD to 80 healthy participants who take the drug at home in the same way that they would take any other medication. MindBio is also targeting Major Depressive Disorder and distress in late-stage cancer patients in its Phase 2 trials which are currently in development and will follow next year.

The approval to continue Phase 1 clinical trials microdosing LSD after the independent safety review is a positive milestone achieved with more than 50% of the participants having now completed the trial.

“We are very pleased to report these safety outcomes in our clinical trials,” said Frederick Pels, CEO of Blackhawk Growth Corp. “These results showcase the caliber of work we are doing, targeting more effective medical treatments for mental health conditions. Throughout these trials, MindBio is solidifying its position as a market leader in the psychedelic research sector. We look forward to updating shareholders with further developments in the near future.”

 

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, and MindBio Therapeutics. Blackhawk continues to bring its investments to cash flow and is growing at an exceeding pace.

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Posted on

Blackhawk Growth’s MindBio Therapeutics Looks to Expand Microdosing Clinical Trials

Blackhawk Growth’s MindBio Therapeutics Looks to Expand Microdosing Clinical Trials

Vancouver, British Columbia – November 01, 2021 – Blackhawk Growth Corp. (CSE:BLR; Frankfurt:0JJ) (the “Corporation” or “Blackhawk”), is pleased to announce that MindBio Therapeutics Pty Ltd (“MindBio”) is working to expand its microdosing clinical trials. MindBio is a multi-disciplinary company pioneering new treatments for mental health conditions using psychedelic medicines, technology assisted mental health interventions and psychedelic assisted psychotherapies.

MindBio is currently undertaking a world’s first clinical trial of its kind. In its phase 1 clinical trial microdosing LSD (Lysergic Acid Diethylamide), MindBio is microdosing LSD to 80 healthy participants who take the drug at home in the same way that they would take any other medication. MindBio will lead phase 2 clinical trials microdosing LSD to patients with major depressive disorder and in patients with late-stage cancer – with those trials set to begin in mid-2022.

Pre-clinical research has demonstrated that psychedelic substances, including LSD, psilocybin, ayahuasca and DMT, affect neuroplasticity after acute and chronic administration. The data generated from in-vitro studies conducted by the Beckley Foundation1 demonstrated neuroplasticity by the presence of Brain Derived Neurotropic Factor (BDNF) in blood plasma. Studies conducted at the University of California, Davis2 have also shown that microdosing psychedelics such as LSD and psilocybin promote increased neurite growth, spine density and synaptogenesis.

MindBio is currently assessing natural psilocybin and potential analogs as a candidate for phase 1 microdosing clinical trials. The company can scale microdosing clinical trials to other substances quickly and cost effectively. MindBio is seeking advice on designing the clinical trial protocols given the potential for psilocybin to treat a number of mental health conditions such as major depressive disorder, PTSD and anxiety.

In addition, Blackhawk’s CEO, Frederick Pels, will be contributing to the psychedelics microdosing discussions at the upcoming Wonderland convention in Miami, where MindBio is a Gold Sponsor. The event is being promoted by conference organiser Microdose as “the biggest psychedelics business event, ever”.

1.https://www.beckleyfoundation.org/2018/06/13/psychedelics-promote-neural-plasticity/

2.https://www.cell.com/cell-reports/fulltext/S2211-1247(18)30755-1

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, and MindBio Therapeutics. Blackhawk continues to bring its investments to cash flow and is growing at an exceeding pace.

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.